HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses   metastatic, castration-resistant prostate cancer

doi:10.1038/onc.2015.444

CORC > 北京大学 > 生命科学学院

	HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer
	Ruscetti, M. ; Dadashian, E. L. ; Guo, W. ; Quach, B. ; Mulholland, D. J. ; Park, J. W. ; Tran, L. M. ; Kobayashi, N. ; Bianchi-Frias, D. ; Xing, Y. ; Nelson, P. S. ; Wu, H.
刊名	ONCOGENE
	2016
关键词	ANDROGEN RECEPTOR BREAST-CANCER DNA-BINDING INCREASED SURVIVAL STEM-CELLS PTEN LOSS HMGI-C ACETYLATION ACTIVATION EXPRESSION
DOI	10.1038/onc.2015.444
英文摘要	PI3K (phosphoinositide 3-kinase)/AKT and RAS/MAPK (mitogen-activated protein kinase) pathway coactivation in the prostate epithelium promotes both epithelial-mesenchymal transition (EMT) and metastatic castration-resistant prostate cancer (mCRPC), which is currently incurable. To study the dynamic regulation of the EMT process, we developed novel genetically defined cellular and in vivo model systems from which epithelial, EMT and mesenchymal-like tumor cells with Pten deletion and Kras activation can be isolated. When cultured individually, each population has the capacity to regenerate all three tumor cell populations, indicative of epithelial-mesenchymal plasticity. Despite harboring the same genetic alterations, mesenchymal-like tumor cells are resistant to PI3K and MAPK pathway inhibitors, suggesting that epigenetic mechanisms may regulate the EMT process, as well as dictate the heterogeneous responses of cancer cells to therapy. Among differentially expressed epigenetic regulators, the chromatin remodeling protein HMGA2 is significantly upregulated in EMT and mesenchymal-like tumors cells, as well as in human mCRPC. Knockdown of HMGA2, or suppressing HMGA2 expression with the histone deacetylase inhibitor LBH589, inhibits epithelial-mesenchymal plasticity and stemness activities in vitro and markedly reduces tumor growth and metastasis in vivo through successful targeting of EMT and mesenchymal-like tumor cells. Importantly, LBH589 treatment in combination with castration prevents mCRPC development and significantly prolongs survival following castration by enhancing p53 and androgen receptor acetylation and in turn sensitizing castration-resistant mesenchymal-like tumor cells to androgen deprivation therapy. Taken together, these findings demonstrate that cellular plasticity is regulated epigenetically, and that mesenchymal-like tumor cell populations in mCRPC that are resistant to conventional and targeted therapies can be effectively treated with the epigenetic inhibitor LBH589.; NIH [T32 CA009056, F32 CA112988-01, P50 CA097186, P01 CA163227, P50 CA092131, R01 CA107166, RO1 CA121110, U01 CA164188]; General Financial Grant from the China Postdoctoral Science Foundation [2015M570010]; Peking-Tsinghua Center for Life Sciences; CIRM [TG2-01169]; Prostate Cancer Foundation Young Investigator Award; Prostate Cancer Foundation; SCI(E); PubMed; ARTICLE; hongwu@pku.edu.cn; 29; 3781-3795; 35
语种	英语
内容类型	期刊论文
源URL	[http://ir.pku.edu.cn/handle/20.500.11897/435994]
专题	生命科学学院
推荐引用方式 GB/T 7714	Ruscetti, M.,Dadashian, E. L.,Guo, W.,et al. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer[J]. ONCOGENE,2016.
APA	Ruscetti, M..,Dadashian, E. L..,Guo, W..,Quach, B..,Mulholland, D. J..,...&Wu, H..(2016).HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.ONCOGENE.
MLA	Ruscetti, M.,et al."HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer".ONCOGENE (2016).